- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01947699
Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide
Diabetes is more likely to occur during pregnancy. When present only in pregnancy it is called gestational diabetes, and it places both mom and baby at risk for complications. Glyburide is one of the currently used treatments for diabetes during pregnancy. This drug is a medication taken by mouth that decreases sugar levels in the blood. It is known to decrease the risk of complications linked to diabetes in pregnancy. Recent studies in pregnancy have described a difference in the way and how well the drug works compared to when used outside of pregnancy.
Oral blood sugar lowering agents are approved by the Food and Drug Administration (FDA) to lower blood sugar in non-pregnant subjects with diabetes. No oral (taken by mouth) blood-sugar lowering agents are FDA approved for use in pregnancy. Although Glyburide is not FDA approved for this use, it is the most commonly used oral blood sugar lowering agent in pregnancy.
This research study will help us learn more about the variations in blood sugar levels in women with diabetes in pregnancy who are taking glyburide and how changes in the timing of when the glyburide is taken would affect blood glucose levels. The goals of this study are:
- To find the how glucose changes throughout the day in women with diabetes in pregnancy receiving glyburide
- To learn the effect of changing the time of taking glyburide on glucose levels
- To learn the effect of changing the time between glyburide doses on glucose levels
- To see if insulin is secreted the same throughout the day in response to a morning dose of glyburide.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Magee Womens Hospital of UPMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant women with gestational diabetes
- Singleton gestation
- Receiving glyburide for the treatment gestational diabetes
- Able to give consent
Exclusion Criteria:
- Women who require insulin for the treatment of gestational diabetes
- Diagnosis of pregestational diabetes
- Poor glycemic control, > 50% of blood glucose values over 200mg/dl prior to start of the study
- Women receiving medications that affect glycemic control e.g. steroids, within a week of enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Glyburide once daily
Timing of glyburide dosing will be changed, glucose will be monitored using continuous a glucose monitor.
|
|
EXPERIMENTAL: Glyburide twice daily
Dose interval and timing of glyburide dose will be changed, glucose will be monitored using continuous a glucose monitor.
|
|
EXPERIMENTAL: Mixed meal tolerance test.
Subjects will be admitted to the Clinical Translational Research Center, receive a Mixed meal tolerance test and have timed blood draws to assess the effect of glyburide on glucose and insulin metabolism.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Glucose levels throughout the day
Time Frame: One week
|
One week
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Hebert MF, Ma X, Naraharisetti SB, Krudys KM, Umans JG, Hankins GD, Caritis SN, Miodovnik M, Mattison DR, Unadkat JD, Kelly EJ, Blough D, Cobelli C, Ahmed MS, Snodgrass WR, Carr DB, Easterling TR, Vicini P; Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther. 2009 Jun;85(6):607-14. doi: 10.1038/clpt.2009.5. Epub 2009 Mar 18.
- Caritis SN, Hebert MF. A pharmacologic approach to the use of glyburide in pregnancy. Obstet Gynecol. 2013 Jun;121(6):1309-1312. doi: 10.1097/AOG.0b013e31829007f0.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPMC_GLY_GDM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes
-
IRCCS Burlo GarofoloCompletedGestational Diabetes | Gestational Diabetes Mellitus | Pregnancy-Induced Diabetes | Diabetes Mellitus, Gestational | Diabetes, Pregnancy InducedIsrael, Italy, Netherlands, Slovenia, Sri Lanka
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of Texas Southwestern Medical CenterCompletedMild Gestational DiabetesUnited States
-
Royal College of Surgeons, IrelandHealth Research Board, IrelandUnknownPre-Gestational Diabetes
-
University of Colorado, DenverKaiser PermanenteCompletedGestational Diabetes MellitusUnited States
-
Intermountain Health Care, Inc.Withdrawn
-
McGill University Health Centre/Research Institute...The Lawson FoundationCompletedGestational Diabetes Mellitus With Baby DeliveredCanada
-
Woman'sBaton Rouge Area FoundationCompletedGestational Diabetes MellitusUnited States
-
Brigham and Women's HospitalUniversity of Colorado, DenverCompletedGestational Diabetes MellitusUnited States
Clinical Trials on Glyburide
-
Bristol-Myers SquibbCompletedDiabetes Mellitus, Non-Insulin-DependentUnited States
-
Bristol-Myers SquibbCompletedDiabetes Mellitus, Non-Insulin-DependentUnited States
-
University of British ColumbiaNovo Nordisk A/SCompleted
-
University of KentuckyRecruiting
-
Eunice Kennedy Shriver National Institute of Child...University of Pittsburgh; University of Washington; University of Texas; RTI International and other collaboratorsUnknownGestational Diabetes MellitusUnited States
-
University of Maryland, BaltimoreNot yet recruitingSarcoidosis, Pulmonary
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States, Germany, Canada, Belgium, Denmark, Spain, Ireland, Netherlands, United Kingdom, Hungary, Italy, France, Austria, Czechia, Norway, Finland, Sweden
-
University of WashingtonGlaxoSmithKline; Seattle Institute for Biomedical and Clinical ResearchCompleted
-
St. Paul Heart ClinicGlaxoSmithKlineCompletedType 2 Diabetes MellitusUnited States
-
Novo Nordisk A/SCompleted